Cartesian Therapeutics (NASDAQ: RNAC) reported its fourth‑quarter 2025 financial results, posting a net loss of $1.39 per share, a miss of 73.75% versus the consensus estimate of $0.80 per share. Revenue for the quarter was $947,000, exceeding the analyst expectation of $94,670 by a factor of ten.
The earnings miss was driven by continued investment in clinical development and manufacturing, with research and development expenses and a one‑time impairment charge accounting for the majority of the loss. The company’s burn rate remains high, reflecting its pre‑revenue stage.
Revenue growth was largely attributable to grant and collaboration income, which rose to $947,000, a ten‑fold increase over the $94,670 forecast. The strong performance in this segment offsets the heavy R&D spend and provides a modest cash cushion.
Compared with the prior quarter, the company’s net loss widened from $35.9 million in Q3 2025 to $35.9 million in Q4 2025, while revenue increased from $452,000 to $947,000. Year‑over‑year, revenue grew from $387,000 in Q3 2024 to $452,000 in Q3 2025, indicating a gradual upward trend in grant and collaboration activity.
CEO Carsten Brunn said the company remains focused on advancing its Phase 3 AURORA trial of Descartes‑08 in myasthenia gravis, noting that enrollment is progressing toward the target of 100 patients. He emphasized that the company’s pipeline progress is a key driver of future revenue potential.
Investors reacted positively to the results, citing the company’s pipeline progress and a cash balance of $126.9 million that is expected to support operations into mid‑2027. The market view highlights confidence in the long‑term value of the mRNA‑CAR‑T platform.
The earnings miss underscores the continued risk associated with the company’s high burn rate, while the revenue beat provides a small cushion. Management will need to secure milestone payments or additional funding to extend the runway beyond the current cash position.
Overall, the Q4 2025 earnings release confirms Cartesian’s status as a high‑burn, pre‑revenue company. The revenue beat offers a modest positive signal, but the significant loss and reliance on future funding remain key considerations for investors.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.